Skip to content

Tecar Therapy in Patients With Lumbar Radiculopathy: A Randomized Controlled Trial

Efficacy of Tecar Therapy Versus Conventional Physical Therapy and Sham Treatment in Patients With Lumbar Radiculopathy: A Randomized Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07480252
Enrollment
90
Registered
2026-03-18
Start date
2026-04-15
Completion date
2028-12-15
Last updated
2026-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Radiculopathy

Keywords

lumbar radiculopathy, Capacitive and Resistive Energy Transfer

Brief summary

Lumbar radiculopathy is a common cause of low back and leg pain, most frequently resulting from lumbar disc herniation and nerve root irritation. Conservative management, including physical therapy modalities and exercise therapy, is generally recommended as first-line treatment for patients without progressive neurological deficits. Tecar therapy (Transfer of Energy Capacitive and Resistive) is a non-invasive electrotherapeutic modality that delivers high-frequency electromagnetic energy to deep tissues and has been proposed to reduce pain, enhance microcirculation, and promote tissue recovery. However, evidence regarding its effectiveness in lumbar radiculopathy remains limited. The aim of this randomized controlled trial is to evaluate the efficacy of Tecar therapy in patients with lumbar radiculopathy and to compare its clinical effects with conventional physical therapy and sham Tecar treatment. A total of 90 participants with unilateral L5 and/or S1 radiculopathy will be randomized into three groups: (1) conventional physical therapy, (2) Tecar therapy combined with standard physical therapy, and (3) sham Tecar therapy combined with standard physical therapy. All participants will receive standardized postural education and a home exercise program. The primary outcome will be pain intensity measured by the Visual Analog Scale (VAS). Secondary outcomes will include functional disability (Oswestry Disability Index), neuropathic pain characteristics (PainDETECT questionnaire), lumbar mobility (Modified-Modified Schober Test), nerve root irritability (Straight Leg Raise test), rescue analgesic consumption, and exercise adherence. Outcomes will be assessed at baseline, post-treatment (week 2), and follow-up visits at weeks 6 and 12.

Detailed description

This assessor-blinded, randomized controlled trial will be conducted in the Department of Physical Medicine and Rehabilitation at İzmir City Hospital, a tertiary-level outpatient center. The study will be designed and reported according to CONSORT recommendations. Participants aged 18-65 years with clinically diagnosed unilateral L5 and/or S1 radiculopathy and symptom duration between 6 weeks and 6 months will be eligible. Diagnosis will primarily be based on clinical findings consistent with radiculopathy, including dermatomal leg pain and supportive neurological examination findings, while lumbar MRI and/or EMG will be used as confirmatory evidence. After written informed consent is obtained, eligible participants will be randomly assigned in a 1:1:1 ratio to one of three groups using computer-generated randomization with concealed allocation. Group 1 will receive conventional physical therapy consisting of hot pack, continuous ultrasound therapy, and transcutaneous electrical nerve stimulation (TENS). Group 2 will receive Tecar therapy in addition to standardized base therapy. Tecar treatment will include capacitive and resistive energy transfer applied to the lumbar paraspinal region and gluteal muscles. Group 3 will receive sham Tecar therapy using the same procedure as the active Tecar protocol but with zero energy output. All groups will additionally receive standardized postural education and a home exercise program. Outcome assessments will be performed by an independent physiatrist blinded to group allocation at four time points: baseline, post-treatment (week 2), and follow-up visits at weeks 6 and 12. The primary outcome will be change in pain intensity measured by the Visual Analog Scale (VAS). Secondary outcomes will include functional disability (Oswestry Disability Index), neuropathic pain features (PainDETECT questionnaire), lumbar mobility (Modified-Modified Schober Test), nerve root irritability assessed with the Straight Leg Raise test, rescue analgesic consumption, and exercise adherence. The study aims to determine whether Tecar therapy provides additional clinical benefit over conventional physical therapy and to evaluate the effectiveness of Tecar therapy beyond placebo effects using a sham-controlled design.

Interventions

Tecar therapy (Transfer of Energy Capacitive and Resistive) will be applied using capacitive and resistive modes to the lumbar paraspinal region and gluteal muscles. Energy output will be adjusted to approximately 50-70% of the device capacity to achieve a comfortably warm sensation. Each session will last approximately 25 minutes and will be performed three times per week for two weeks. All applications will be delivered using a hypothermic electrode head.

Sham Tecar therapy will be delivered using the same device, electrode head, treatment duration, and therapist contact as the active Tecar therapy protocol. However, the device will be set to zero intensity output, preventing the delivery of electromagnetic energy or heat. This procedure is designed to mimic the active intervention while providing no therapeutic effect.

PROCEDUREConventional Physical Therapy

Conventional physical therapy will include a combination of hot pack, continuous ultrasound therapy, and transcutaneous electrical nerve stimulation (TENS) applied to the lumbar region. Treatment sessions will be conducted five times per week for two weeks. Participants will also receive standardized postural education and a home exercise program.

Sponsors

Izmir City Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participants allocated to the Tecar therapy and sham Tecar therapy groups were blinded to treatment allocation, as both interventions used identical procedures and a hypothermic electrode head, with the sham device delivering zero energy output. Outcome assessments were performed by an independent physiatrist blinded to group allocation. Blinding of participants and therapists was not possible in the conventional physical therapy group due to the nature of the interventions. Therefore, the trial is designed as an assessor-blinded randomized controlled trial.

Intervention model description

Participants will be randomly assigned in a 1:1:1 ratio to one of three parallel groups: conventional physical therapy, Tecar therapy combined with standardized physical therapy, or sham Tecar therapy combined with standardized physical therapy. All groups will receive standardized postural education and a home exercise program. The study follows a parallel-group design in which participants remain in their assigned intervention group throughout the study perio

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Adults aged 18-65 years Clinical diagnosis of unilateral L5 and/or S1 lumbar radiculopathy Symptom duration between 6 weeks and 6 months Average radicular pain intensity ≥3 on the Visual Analog Scale (VAS) during the previous month Availability of lumbar MRI and/or EMG performed within the previous 6 months Willingness to participate and ability to provide written informed consent -

Exclusion criteria

Bilateral lumbar radiculopathy Lumbar spinal canal stenosis confirmed by imaging or suspected clinically (e.g., neurogenic claudication) Lower limb muscle strength \<4/5 according to the Medical Research Council (MRC) scale Use of analgesic medications other than paracetamol during the study period Physical therapy treatment for low back or radicular pain within the past 3 months Contraindications to physical therapy modalities or Tecar therapy Previous lumbar spine surgery or interventional spinal procedures within the last 6 months Pregnancy, malignancy, or systemic neurological or rheumatologic disease Advanced spinal or lower extremity deformities (e.g., scoliosis \>20°, grade 3-4 spondylolisthesis, vertebral fracture, advanced coxarthrosis) Inability to complete the intervention protocol or follow-up assessments \-

Design outcomes

Primary

MeasureTime frameDescription
Pain Intensity (Visual Analog Scale, VAS)Baseline, Week 2 (post-treatment), Week 6, and Week 12Pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS), where 0 represents "no pain" and 10 represents "worst imaginable pain." Participants will rate their average lumbar and radicular pain intensity during the previous 7 days.

Secondary

MeasureTime frameDescription
Neuropathic Pain Characteristics (PainDETECT Questionnaire)Baseline, Week 2, Week 6, and Week 12Neuropathic pain features will be assessed using the PainDETECT Questionnaire, a validated self-report instrument ranging from -1 to 38 points. Higher scores indicate a greater likelihood of neuropathic pain components.
Lumbar Mobility (Modified-Modified Schober Test)Baseline, Week 2, Week 6, and Week 12Lumbar spine mobility will be assessed using the Modified-Modified Schober Test. The distance between two skin marks placed over the lumbar spine will be measured during maximal forward flexion.
Nerve Root Irritability (Straight Leg Raise Test)Baseline, Week 2, Week 6, and Week 12The Straight Leg Raise (SLR) test will be used to assess nerve root irritability. The angle at which radicular pain is reproduced during passive leg elevation will be measured using a goniometer.

Countries

Turkey (Türkiye)

Contacts

CONTACTErtan Yilmaz, Medical Doctor, Specialist
ertnyilmzz@gmail.com+905318431901
CONTACTErtam Yilmaz, Medical Doctor, Specialist
ertnyilmzz@gmail.com
PRINCIPAL_INVESTIGATORErtan Yilmaz, Medical Doctor, Specialist

Izmir City Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026